AAM Steps Into GSK-Teva Case To Defend Carve-Outs
Ruling On Skinny Labels Must Not Become ‘Road Map’ For Originators
The AAM has stepped into controversial litigation between Teva and GSK over generic labelling carve-outs, urging the US Court of Appeals for the Federal Circuit to rehear the case to prevent the rules on so-called skinny labels from being subverted.
